Aligning New Approaches to Accelerate the Development of Non-opioid Analgesic Therapies

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2020 Oct 15

PMID 33058022

Citations 2

Authors

Christine N Sang

William K Schmidt

Affiliations

Soon will be listed here.

Citing Articles

The μ-opioid receptor differentiates two distinct human nociceptive populations relevant to clinical pain.

Staedtler E, Sapio M, King D, Maric D, Ghetti A, Mannes A Cell Rep Med. 2024; 5(10):101788.

PMID: 39413733 PMC: 11513826. DOI: 10.1016/j.xcrm.2024.101788.

Novel Applications of NSAIDs: Insight and Future Perspectives in Cardiovascular, Neurodegenerative, Diabetes and Cancer Disease Therapy.

Kadusevicius E Int J Mol Sci. 2021; 22(12).

PMID: 34205719 PMC: 8235426. DOI: 10.3390/ijms22126637.

References

Tao X, Lee M, Donnelly C, Ji R . Neuromodulation, Specialized Proresolving Mediators, and Resolution of Pain. Neurotherapeutics. 2020; 17(3):886-899. PMC: 7609770. DOI: 10.1007/s13311-020-00892-9. View

Hegazy N, Rezq S, Fahmy A . Mechanisms Involved in Superiority of Angiotensin Receptor Blockade over ACE Inhibition in Attenuating Neuropathic Pain Induced in Rats. Neurotherapeutics. 2020; 17(3):1031-1047. PMC: 7609714. DOI: 10.1007/s13311-020-00912-8. View

Goldstein P, Ashar Y, Tesarz J, Kazgan M, Cetin B, Wager T . Emerging Clinical Technology: Application of Machine Learning to Chronic Pain Assessments Based on Emotional Body Maps. Neurotherapeutics. 2020; 17(3):774-783. PMC: 7609511. DOI: 10.1007/s13311-020-00886-7. View

Li J, Zhang L, Xu C, Lin Y, Zhang Y, Wu H . Prolonged Use of NMDAR Antagonist Develops Analgesic Tolerance in Neuropathic Pain via Nitric Oxide Reduction-Induced GABAergic Disinhibition. Neurotherapeutics. 2020; 17(3):1016-1030. PMC: 7609518. DOI: 10.1007/s13311-020-00883-w. View

Bannister K, Dickenson A . Central Nervous System Targets: Supraspinal Mechanisms of Analgesia. Neurotherapeutics. 2020; 17(3):839-845. PMC: 7609795. DOI: 10.1007/s13311-020-00887-6. View

Bennett M, Bennett F, Liddelow S, Ajami B, Zamanian J, Fernhoff N . New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A. 2016; 113(12):E1738-46. PMC: 4812770. DOI: 10.1073/pnas.1525528113. View

St Clair C, Papadopoulos E . Considerations in the Assessment of Clinical Benefit with a Focus on Pain: a Regulatory Perspective. Neurotherapeutics. 2020; 17(3):770-773. PMC: 7609809. DOI: 10.1007/s13311-020-00906-6. View

Ciotu C, Fischer M . Novel Analgesics with Peripheral Targets. Neurotherapeutics. 2020; 17(3):784-825. PMC: 7609673. DOI: 10.1007/s13311-020-00937-z. View

Wong C, Siah K, Lo A . Estimation of clinical trial success rates and related parameters. Biostatistics. 2018; 20(2):273-286. PMC: 6409418. DOI: 10.1093/biostatistics/kxx069. View

10.

Song G, Yang Z, Guo J, Zheng Y, Su X, Wang X . Interactions Among lncRNAs/circRNAs, miRNAs, and mRNAs in Neuropathic Pain. Neurotherapeutics. 2020; 17(3):917-931. PMC: 7609633. DOI: 10.1007/s13311-020-00881-y. View

11.

Ray P, Torck A, Quigley L, Wangzhou A, Neiman M, Rao C . Comparative transcriptome profiling of the human and mouse dorsal root ganglia: an RNA-seq-based resource for pain and sensory neuroscience research. Pain. 2018; 159(7):1325-1345. PMC: 6008200. DOI: 10.1097/j.pain.0000000000001217. View

12.

Donnelly C, Andriessen A, Chen G, Wang K, Jiang C, Maixner W . Central Nervous System Targets: Glial Cell Mechanisms in Chronic Pain. Neurotherapeutics. 2020; 17(3):846-860. PMC: 7609632. DOI: 10.1007/s13311-020-00905-7. View

13.

Iyengar S, Woller S, Hommer R, Beierlein J, Wright C, Tamiz A . Critical NIH Resources to Advance Therapies for Pain: Preclinical Screening Program and Phase II Human Clinical Trial Network. Neurotherapeutics. 2020; 17(3):932-934. PMC: 7609631. DOI: 10.1007/s13311-020-00918-2. View

14.

Maier D, Hill G, Ding M, Tuke D, Einstein E, Gurley D . Pre-clinical validation of a novel alpha-7 nicotinic receptor radiotracer, [(3)H]AZ11637326: target localization, biodistribution and ligand occupancy in the rat brain. Neuropharmacology. 2011; 61(1-2):161-71. DOI: 10.1016/j.neuropharm.2011.03.024. View

15.

Ingusci S, Verlengia G, Soukupova M, Zucchini S, Simonato M . Gene Therapy Tools for Brain Diseases. Front Pharmacol. 2019; 10:724. PMC: 6613496. DOI: 10.3389/fphar.2019.00724. View

16.

Wangzhou A, McIlvried L, Paige C, Barragan-Iglesias P, Shiers S, Ahmad A . Pharmacological target-focused transcriptomic analysis of native vs cultured human and mouse dorsal root ganglia. Pain. 2020; 161(7):1497-1517. PMC: 7305999. DOI: 10.1097/j.pain.0000000000001866. View

17.

Hughes D, Todd A . Central Nervous System Targets: Inhibitory Interneurons in the Spinal Cord. Neurotherapeutics. 2020; 17(3):874-885. PMC: 7641291. DOI: 10.1007/s13311-020-00936-0. View

18.

Wagner K, Gomes A, McReynolds C, Hammock B . Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain. Neurotherapeutics. 2020; 17(3):900-916. PMC: 7609775. DOI: 10.1007/s13311-020-00916-4. View

19.

Li X, Chen Q, Zhuo M . Neuronal Adenylyl Cyclase Targeting Central Plasticity for the Treatment of Chronic Pain. Neurotherapeutics. 2020; 17(3):861-873. PMC: 7609634. DOI: 10.1007/s13311-020-00927-1. View

20.

Krajewski J . P2X3-Containing Receptors as Targets for the Treatment of Chronic Pain. Neurotherapeutics. 2020; 17(3):826-838. PMC: 7609758. DOI: 10.1007/s13311-020-00934-2. View